Rivera-Luna R, Alter-Molchadsky N, Cardenas-Cardos R, Martínez-Guerra G
Department of Oncology, Instituto Nacional de Pediatría, Delegación Coyoacán México, D.F. Mexico.
Med Pediatr Oncol. 1996 May;26(5):334-43. doi: 10.1002/(SICI)1096-911X(199605)26:5<334::AID-MPO6>3.0.CO;2-J.
This is a retrospective study of 55 children under the age of 2 years diagnosed with Langerhans cell histiocytosis (LCH). They were classified according to age and organ function and dysfunction following Lahey's criteria. The studied population was divided into four groups by age of diagnosis (0-6, 7-12, 13-18, and 19-24 months). Statistical analysis showed no significant difference in outcome between age groups, although the population under 6 months had a 81.3% fatality rate. The presence of organ dysfunction was a major cause of death in all age groups, being statistically significant in outcome (P > 0.005) compared with patients without organ dysfunction. The presence of thrombocytopenia and/or respiratory dysfunction was also highly associated with a fatal outcome. In the surviving population, no second malignancies have been reported. The late secondary effects of therapy include endocrine, orofacial, and osseous pathologies.
